Richard E. Pratley, MD, reports the first data on oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
ICYMI: Presenter Perspectives: Effect of Oral Semaglutide With or Without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
